我们正在向临床应用推进，并且致力于开发高度差异化的TCR-T疗法，以在解决实体瘤患者未满足的治疗需求的目标上取得进展。”参考资料：https://medigene.com/new-data-presented-at-aacr-shows-enhanced-t-cell-functionality-of-mdg1015-in-solid-tumors/
近年来,该团队在免疫检查点抗体药物作用机制方面开展了系列研究工作,在PD-1、PD-L1及CTLA-4等靶点抗体药物的结合机制,PD-1糖基化修饰对抗体药物影响等方面取得新进展,研究成果相继发表在Nature Communications、Cell Research、Protein Cell 等,为相关靶点药物开发提供了重要的理论依据。
[6] Gulhati P, Schalck A, Jiang S, et al. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat Cancer. 2022 Dec 30. doi: 10.1038/s43018-022-00500-z. 版权声明 本网站所有注明“来源:生物谷...
4月19日, Medigene AG于佛罗里达举行的AACR 2023年年会上展示了其自研疗法MDG1015的临床前数据。MDG1015是一种结合公司的PD1-41BB开关受体技术开发的针对NY-ESO-1(纽约食管鳞状细胞癌1)的T细胞受体工程T细胞(T…
为了充分发挥4-1BB激动剂的潜力并促进最佳剂量发现,理想的联合是使得4-1BB表达增加和更匀质。例如可能的联合伙伴是T-cell engagers从而促进CD3介导的4-1BB在 CD8+T细胞的上调或ADCC-inducing antibodies导致NK细胞的4-1BB上调。促进T细胞启动和激活的标准...
随着嵌合抗原受体t细胞(chimericantigenreceptor-tcell,car-t)技术的不断发展,目前car-t主要可划分为四代。 第一代car-t细胞由胞外结合区-单链抗体(single-chainfragmentvariable,scfv)、跨膜区(transmembraneregion,tm)和胞内信号区——免疫受体酪氨酸活化基序(immunoreceptortyrosine-basedactivationmotif,itam)组成,其中...
Adoptive immunotherapy, a promising treatment option, uses genetically modified T cells to eliminate tumors. However, efficacy of T cell immunotherapy is dampened by limited costimulation as well as increased inhibitory and death signals in the TME. We previously showed enhanced therapeutic efficacy by ...
Since single and dual ICTs were not curative, T cell-activating ICTs were combined with a CXCR1/2 inhibitor targeting immunosuppressive myeloid cells. Triple therapy resulted in durable complete responses. Given similar profiles in human PDAC and the availability of these agents for clinical testing,...
Programmed Cell Death Protein 1 (PD-1),一种在激活的 T 细胞上表达的受体,与其配 体 PD-L1 和 PD-L2 结合,负向调节免疫反应。 PD-1 配体存在于大多数癌症中,PD-1:PD- L1/2 相互作用会抑制 T 细胞活性,并使癌细胞逃避免疫监视。 PD1/PDL1 信号转导通路是 肿瘤免疫抑制的重要组成部分,可以抑制 T ...
Activated T cells also express CD137, and engagement with CD137L enhances T cell proliferation, IL-2 secretion, survival, and cytotoxic activity. CD137L is also expressed on a majority of B-cell lymphomas, including mantle cell lymphoma, follicular lymphoma, and diffuse large ...